跳到主要內容

Strom Carrie C 的 Form 4 申報

AbbVie Inc.(ABBV),2023/2/21 申報

申報編號
0001415889-23-002946
申報時間
2023/2/21
交易日
2023/2/16-2/21
申報延遲
5 天
10b5-1 計畫
表單沒有這欄(2023 年以前)

這份申報列了 10 筆非衍生性交易、3 筆衍生性交易。公開市場賣出合計 $431.1 萬。交易後 5 天申報。

申報人

一份 Form 4 可以有好幾位申報人,例如本人與他控制的基金。各交易表上顯示的是第一位。

這份申報的申報人
申報人與公司的關係
Strom Carrie CCIK 0001811896高階主管(SVP & PRES GLOBAL ALLERG AESTH)

非衍生性證券(表 I)

普通股等股票的取得與處分,每一列是申報上的一筆。

非衍生性證券的交易
交易日證券交易股數價格金額交易後持股持有方式旗標
2023/2/16Common Stock, $0.01 par valueA公司授予取得+6,546$0.00$047,209直接
2023/2/16Common Stock, $0.01 par valueA公司授予取得+5,074$0.00$052,283直接
2023/2/21Common Stock, $0.01 par valueM行使選擇權取得+7,809$56.93+$444,566.3760,092直接
2023/2/21Common Stock, $0.01 par valueM行使選擇權取得+6,370$67.25+$428,382.566,462直接
2023/2/21Common Stock, $0.01 par valueS賣出處分−5,615$150.71F3−$846,236.6560,847直接
2023/2/21Common Stock, $0.01 par valueS賣出處分−7,780$151.28F4−$1,176,958.453,067直接
2023/2/21Common Stock, $0.01 par valueS賣出處分−6,533$150.74F5−$984,784.4246,534直接
2023/2/21Common Stock, $0.01 par valueS賣出處分−7,646$151.29F6−$1,156,763.3438,888直接
2023/2/21Common Stock, $0.01 par valueS賣出處分−567$150.78F7−$85,492.2638,321直接
2023/2/21Common Stock, $0.01 par valueS賣出處分−400$151.34F8−$60,53637,921直接

衍生性證券(表 II)

選擇權、認股權證、限制型股票單位等。股數是標的股票的股數;單價與金額是衍生證券本身的價格,交易後持有是衍生證券的單位數。

衍生性證券的交易
交易日證券交易標的股數單價金額交易後持有持有方式旗標
2023/2/16Common StockA公司授予取得+16,205$0.00$016,205直接
2023/2/21Common StockM行使選擇權處分−7,809$56.93−$444,566.370直接
2023/2/21Common StockM行使選擇權處分−6,370$67.25−$428,382.50直接

附註與備註

本站收錄交易價格引用的附註、修正申報(Form 4/A)的全部附註,以及申報的備註。其他附註,例如間接持有的方式、交易計畫的細節,請看 SEC EDGAR 上的原文。

F3

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.12 to $151.11, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

表 I 有 1 筆交易的價格引用這則附註。

F4

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.12 to $151.51, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

表 I 有 1 筆交易的價格引用這則附註。

F5

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.12 to $151.11, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

表 I 有 1 筆交易的價格引用這則附註。

F6

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.12 to $151.51, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

表 I 有 1 筆交易的價格引用這則附註。

F7

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.12 to $151.10, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

表 I 有 1 筆交易的價格引用這則附註。

F8

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.15 to $151.42, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

表 I 有 1 筆交易的價格引用這則附註。

備註

The option exercise and sale transactions were made pursuant to a previously adopted plan complying with Rule 10b5-1(c).

看 SEC EDGAR 上的完整原文 (在新分頁開啟)